Author: Editor

Philadelphia, PA (September 10, 2019) – Oncoceutics, Inc. announced a scientific publication in the Journal of Neuro-Oncology describing a complete response and other forms of clinical benefit in pediatric and adult H3 K27M-mutant glioma patients treated with ONC201 on expanded access protocols. This manuscript details radiographic findings and other clinical outcomes in eighteen H3 K27M-mutant glioma patients who were enrolled on expanded access protocols. These patients initiated ONC201 after prior radiation, and in many cases after also failing additional chemotherapy, a disease setting in neuro-oncology where no available therapies have been proven effective. Overall findings include disease stabilization and radiographic regressions after…

– 20 Patients Remain Progression Free on Tivozanib Arm vs. 2 on Sorafenib Arm – – Company Plans to Discuss Updated Results with FDA – – AVEO to Host Conference Call Today at 8:00 am Eastern Time – CAMBRIDGE, Mass. – September 10, 2019 – AVEO Oncology (NASDAQ: AVEO) today announced results from the second prespecified analysis of overall survival (OS) in the TIVO-3 trial. TIVO-3 is the Company’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA®) to sorafenib in 350 subjects with highly refractory metastatic renal cell carcinoma (RCC). These results include an OS hazard ratio…

Program includes debate and interactive case studies on emerging cancer care practices. #NCCNhem19. SAN FRANCISCO, CA [September 10, 2019] — World-renowned experts on blood cancers are meeting in San Francisco on September 27-28, to help clinicians stay up-to-date on new, practice-changing strategies to manage patients with hematologic malignancies, at the NCCN 2019 Annual Congress: Hematologic Malignanciesâ„¢, presented by the National Comprehensive Cancer Network® (NCCN®), and co-chaired by Ranjana H. Advani, MD, Saul Rosenberg Professor of Lymphoma, Stanford University School of Medicine and Andrew D. Zelenetz, MD, PhD, Medical Director, Quality Informatics, Memorial Sloan Kettering Cancer Center. The Congress will address new, emerging, and novel therapeutic agents, diagnostics, and other advances in…

Dr. Neal provides insight on the horizon for the upcoming year.

Dr. Neal explains the unmet needs for this patient population.

In the Phase III CASPIAN trial IMFINZI at a fixed, convenient dose improved survival with either a cisplatin or carboplatin chemotherapy backbone AstraZeneca today presented detailed results from the Phase III CASPIAN trial, showing IMFINZI® (durvalumab) significantly improved overall survival (OS) in patients with previously-untreated extensive-stage small cell lung cancer (SCLC). IMFINZI in combination with four cycles of standard-of-care (SoC) chemotherapy (etoposide with either cisplatin or carboplatin) demonstrated a statistically-significant and clinically-meaningful improvement in OS vs. SoC chemotherapy consisting of up to six cycles of chemotherapy and optional prophylactic cranial irradiation (PCI). The risk of death was reduced by 27% (equal to…

Phase One Study Shows Novel KRAS Inhibitor Well Tolerated by Patients with Adenocarcinoma and Non-Small Cell Lung Cancer Barcelona–Sunday, September 8 at 9:45 a.m. CEST — A clinical trial testing the toxicity of a KRAS inhibitor demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non-small cell lung cancer harboring KRAS G12C mutation, according to Ramaswamy Govindan, M.D., from the Siteman Cancer Center at Washington University School of Medicine, St. Louis. The KRAS G12C mutation is found in approximately 14 percent of patients with lung adenocarcinoma and 11 percent of patients with non-small cell lung…

(9 September, Tokyo) In a recent study published in the journal Haematologica, researchers at Juntendo University used stem cell technology to produce immune cells with an enhanced ability to fight aggressive tumors of the nasal cavity. A lesser known but invasive form of cancer prevalent in Asian countries is extranodal natural killer/T cell lymphoma (ENKL). While it starts within the nasal cavity it often spreads to the digestive system, kidneys and bone marrow. At present, the enzymeL-asparaginase is the only therapy available for treating ENKL. However, many patients do not respond well to L-asparaginase thereby greatly decreasing their chances of prolonged survival. Now,…

Phase 3 Data for KEYTRUDA® (pembrolizumab) as Neoadjuvant Therapy in Combination with Chemotherapy in Patients with Triple-Negative Breast Cancer (KEYNOTE-522) to be Featured in ESMO Presidential Symposium and Official Press Program Data for LYNPARZA Included in ESMO Presidential Symposium and Official Press Program: in Metastatic Castration-Resistant Prostate Cancer (PROfound) and in Advanced Ovarian Cancer (PAOLA-1) Monday, September 9, 2019 6:45 am EDT KENILWORTH, N.J.–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from its broad oncology portfolio and pipeline will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain,…

54% of 13 Evaluable Non-Small Cell Lung Cancer Patients Experienced a Partial Response at the Target Dose of 960 mg in the   Ongoing Phase 1 Study   46% of Patients had Stable Disease for a Disease Control Rate of   100% at the Target Dose   FDA Grants AMG 510 Fast Track Designation for Previously Treated   Metastatic NSCLC With KRAS G12C Mutation   THOUSAND OAKS, Calif. (Sept. 8, 2019) — Amgen (NASDAQ:AMGN) today announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors. AMG 510 is a…

Dr. Neal provides the most commonly asked questions from colleagues and the recent findings in NSCLC.

Dr. Neal describes TAK-788’s safety profile and the side effects that come along with the drug’s use.

Dr. Neal provides details on TAK-788 Phase 1/2 study.

Dr. Neal explains what EGFR exon 20-mutant NSCLC is and how many patients have this particular mutation.

TORONTO, ON and LONDON, UK / ACCESSWIRE / September 6, 2019 / Soricimed Biopharma Inc. (“Soricimed”), a clinical-stage pharmaceutical company discovering and developing first-in-class targeted cancer therapeutics, today announced that it has entered into a strategic alliance with Image Analysis Group (“IAG”), a UK-based company with unique expertise in medical imaging and artificial intelligence (“AI”)-based image analytics, whereby the companies will join their efforts in the development of Soricimed’s lead anti-cancer drug candidate, SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel. The partners will validate the use of advanced image assessment and AI-derived markers to predict patient treatment response in…

FINDINGS Breast cancer surgeons performing lumpectomies seek to spare healthy breast tissue while removing all cancerous cells, but determining appropriate margins and avoiding follow-up surgeries are ongoing challenges. This retrospective, single-institution review found that intraoperative teamwork between a breast cancer surgeon and a dedicated breast pathologist – utilizing tissue-marking ink and gross examination with magnification to evaluate margins – is an accurate, rapid and cost-effective means of significantly reducing the need for second-surgery margin re-excisions or mastectomies.   BACKGROUND Several studies have shown significantly increased local breast cancer recurrence rates in patients with low-stage breast carcinoma in whom margins were…

Hamburg, Germany and Baltimore, Maryland, 2019.09.04 ̶ Using Sysmex Inostics’ novel SafeSEQ next- generation sequencing cell-free DNA technology, investigators from the Biomedical Research Institute of Malaga [(IBIMA)-CIMES-UMA, Malaga Spain] and collaborators have published the first pilot study to examine the use of a non-invasive liquid biopsy in early diagnosis of breast cancer. This study was unique in that the ctDNA analyses was performed before any invasive diagnostic procedure or treatment. The SafeSEQ liquid biopsy technology has shown sensitivity down to five mutant molecules in a background of ten thousand normal ones (or 0.05% mutant allele frequency also known as MAF).…

Yes. Screening techniques for ovarian cancer are nonexistent. Studies have looked at combinations of blood markers and ultrasounds, but they did not show a survival improvement. Ultimately, if a patient undergoes screening, it should lead to some improvement in outcome or prevention of the cancer altogether. John M. NakayamaAI can help us in this area because cancer results from a combination of genetic and environmental factors. We can try to account for more factors using AI, such as other genetic markers, epigenetic markers, changes in lipids, earlier CT or ultrasound findings that could be predictive. Putting those together would generate…

(Reuters Health) – Cancer specialists only rarely advise patients on lifestyle changes that could improve overall health and possibly also reduce the risk of recurrence, a new survey suggests. The survey of doctors from a Midwestern health system found that oncologists were far less likely than primary care physicians to offer advice on health promotion strategies, such as weight loss and smoking cessation, researchers reported in the journal Cancer. With oncologists reticent to offer advice on lifestyle changes, the onus may fall upon patients to bring the topic up and to find ways on their own to address changes, said…

– Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients;(1) EVALUATE-HF results complement findings(2) - PROVE-HF establishes significant correlation between improvement in widely used cardiac biomarker and positive changes in heart structure and ability to pump blood in patients taking Entresto(1) – Safety and tolerability of Entresto were comparable to previously reported findings(1,2,3) EAST HANOVER, N.J., Sept. 2, 2019 /PRNewswire/ – Novartis announced today results from two new clinical trials evaluating improvement in heart structure and function and long-term safety of Entresto® (sacubitril/valsartan) in…

(New York, NY – September 3, 2019) – September is Thyroid Cancer Awareness Month,and doctors in the Mount Sinai Health System are promoting early detection by encouraging high-risk groups to be aware of symptoms. “While the overall prognosis for the majority of thyroid cancers is excellent, early diagnosis and treatment are critical to improve survival and decrease the risk of future recurrence. In addition, in many cases, early diagnosis and appropriate surgical management often obviates the need for additional therapies such as radiation or chemotherapy,” says Brett Miles, MD, DDS, Professor and Co-Chief of the Division of Head and Neck Oncology…

Drs. Jack West, Charu Aggarwal, and Benjamin Levy recently gathered to review top discussion points for Lung Cancer from ASCO 2019. In this video, the doctors discuss long term outcomes with Pembrolizumab. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Sarmad Sadeghi, MD of USC Norris Comprehensive Cancer Center explains awaiting approval from the FDA in bladder and prostate cancer.

Sarmad Sadeghi, MD of USC Norris Comprehensive Cancer Center explains the role of nephrectomy is getting smaller and smaller in kidney cancer.

John Fruehauf, MD disucsses whether the CheckMate 204 data will affect treatment selection in brain metastases

John Fruehauf, MD of UC Irvine Health discusses new first-line therapy for asymptomatic melanoma brain metastases.         new first-line therapy, asymptomatic melanoma brain metastases, uc irvine health, checkmate 204 study, study, checkmate 204

John Fruehauf, MD of UC Irvine Health explains clinicians could change the way they manage their patients by lowering doses and possibly impacting treatment that way.

John Fruehauf, MD provides insight on how to address toxicity that is causing colitis.

John Fruehauf, MD of UC Irvine Health discusses lowering toxicity through alternate dosing.

John Fruehauf, MD of UC Irvine Health presents whether data practice will change for clinicians.

John Fruehauf, MD of UC Irvine Health explains how INMC data has impacted surgical oncologists.

John Fruehauf, MD of UC Irvine Health discusses IMNC (International Neoadjuvant Melanoma Consoritum) Abstract 9503.

Afsaneh Barzi, MD of Keck School of Medicine discusses the factors to consider in the IDEA collaboration.

Afsaneh Barzi, MD of Keck School of Medicine provides the impact the IDEA data will have on clinicians.

Afsaneh Barzi, MD of Keck School of Medicine explains IDEA collaboration findings in 3 versus 6 months for stage 3 colon cancer.

Afsaneh Barzi, MD of Keck School of Medicine presents the IDEA (International Duration Evaluation of Adjuvant Chemotherapy) collaboration which investigated the adjuvant oxaliplatin-based therapy for patients with high-risk stage II colorectal cancer.

Afsaneh Barzi, MD of Keck School of Medicine discusses the immediate implications in the POLO trial is mandatory germline testing for all patients with pancreatic cancer.

Afsaneh Barzi, MD of Norris Cancer Center provides insight on the still unanswered questions in the POLO study.

Afsaneh Barzi, MD of Norris Cancer Center explains the phase III POLO trial, a maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer.

Philadelphia, PA (August 26, 2019) – Oncoceutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for ONC206, allowing the first-in-human trial of the compound. ONC206 is the first of the family of drug candidates, which we call “imipridones”, that possess the same core chemical structure as ONC201. The first clinical trial for ONC206 in adults with primary central nervous system neoplasms will be conducted at the National Cancer Institute (NCI) under the leadership of Mark Gilbert, MD, Chief of the Neuro-Oncology Branch, Center for Cancer Research (CCR) and Brett Theeler,…

Jacob Sands, MD explica lurbinectedin presentado en ASCO 2019.

Jacob Sands, MD discusses lurbinectedin providing another treatment option for patients and practitioners.

Jacob Sands, MD discusses lurbinectedin presented at ASCO 2019.

Jacob Sands, MD provides data and updates on lurbinectedin in small cell lung cancer immunotherapy treatment.

Pascal Besman, COO Pharmamar – PharmaMar to submit New Drug Application (NDA) for lurbinectedin under accelerated approval in SCLC in the USA. Pascal Besman, Pharmamar COO discusses advantages and potential limitations of the new drug.

HATFIELD, Pa. and CLEVELAND, Aug. 27, 2019 /PRNewswire/ — Genisphere LLC and University Hospitals Cleveland Medical Center announced a partnership to study and develop unique strategies to treat pancreatic cancer. According to their agreement, investigators will optimize 3DNA®-based therapeutics designed to target and kill pancreatic tumors. Projects will include delivering a variety of therapeutic cargos, including small molecules and siRNA, formulated with pancreatic tumor-targeting molecules on Genisphere’s 3DNA® nanocarrier. Jordan Winter, MD, Chief of the Division of Surgical Oncology at University Hospitals Cleveland Medical Center and Director of Surgical Services at UH Seidman Cancer Center, is the lead researcher on…

Lurbinectedin, a potential practice changing drug if approved, will be the only agent available in SCLC tested with immunotherapy. PharmaMar to submit New Drug Application (NDA) for lurbinectedin under accelerated approval in SCLC in the USA.         lurbinectedin, potential practice changing drug, new drug application (nda), nda, pharmamar, immunotherapy, sclc

PharmaMar to submit New Drug Application (NDA) for lurbinectedin under accelerated approval in SCLC in the USA. Hossein Borghaei, MD discusses the recent data released and advantages and potential limitations of the new drug.

Niraparib demonstrated clinically relevant activity among women with heavily pretreated ovarian cancer, particularly those with homologous recombination deficiency-positive, platinum-sensitive disease, according to findings from the phase 2 QUADRA study published in The Lancet Oncology. The results, which also showed no new safety signals, support extending the use of poly(ADP-ribose) polymerase (PARP) inhibitors to a wider population of women with late-line ovarian cancer, including those without BRCAmutations, according to the researchers. “This is another piece of the puzzle that helps our patients live longer,” Kathleen Moore, MD, associate director of clinical research at Stephenson Cancer Center at University of Oklahoma College of Medicine, said in a press…

Jack Stewart, CSO of Soricimed Biopharma explains SOR-C13 is the leading drug in a phase 1b clinical trial in late stage pancreatic cancer.

Jack Stewart, CSO of Soricimed Biopharma discusses SOR-C13, a selective inhibitor of TRPV6, binds with affinity and disrupts how TRPV6 functions.

Jack Stewart, CSO of Soricimed Biopharma explains SOR-C13 potentially shows promise in ovarian, metastatic prostate and pancreatic cancer.

Data from largest population study to date help identify at-risk individuals, could inform screening initiatives Published on: August 08, 2019 (WASHINGTON, August 8, 2019) — New data suggest that people who have a parent, sibling, or child with blood cancer have a higher likelihood of being diagnosed with the disease. The study published online today in Blood offers the first evidence that such familial risks exist across the spectrum of hematologic malignancies. Age of diagnosis, whether the relative is a parent, sibling, or child, and the number of affected first-degree relatives play a defining role in the relative risk of developing certain blood cancers, according to the study. “This information improves our understanding of the causes of – and potential inherited predisposition to – blood cancers and should inform the identification and characterization of genetic risk factors for blood cancer, as well as how we best clinically…

Findings may guide decisions about which patients will benefit most from treatment with sorafenib Advanced hepatocellular carcinoma (HCC) is commonly treated with sorafenib Subset of CD8+ cells are biomarker linked with survival benefit, team shows Evidence could lead to more individualized treatments for liver cancer patients  BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center immunology researchers have uncovered a biomarker that may help explain why some patients respond better than others to a common chemotherapy treatment for liver cancer. They hope that their analysis of immune responses among patients receiving sorafenib can lead to more individualized treatment options and better…

TAGRISSO is the only medicine demonstrating statistically-significant overall survival benefit in this setting. Also increased the time patients with central nervous system metastases lived without disease progression   (WILMINGTON, Del., August 9, 2019) AstraZeneca today announced positive overall survival (OS) results from the Phase III FLAURA trial, a randomized, double-blinded, multicenter trial of TAGRISSO in previously-untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) mutations.   TAGRISSO showed a statistically-significant and clinically-meaningful improvement in OS, a secondary endpoint in the FLAURA Phase III trial, compared with erlotinib or gefitinib both of which were previous standard-of-care (SoC) treatments…

Adjuvant chemoradiotherapy improved overall survival for women with locally advanced endometrial cancer compared with radiation alone, a post-hoc analysis of the phase III PORTEC-3 trial found. With adjustment for stratification factors, overall survival (OS) at 5 years was 81.4% in the chemoradiotherapy group compared with 76.1% in the group receiving radiotherapy alone (adjusted HR 0.70, 95% CI 0.51-0.97, P=0.034), reported Stephanie de Boer, MD, of Leiden University Medical Center in the Netherlands, and colleagues.   And in their study of over 600 patients with stage I-III endometrial cancer, failure-free survival (FFS) at 5 years was 76.5% with chemoradiotherapy versus 69.1% with…

NEW YORK — While new drugs for cancer are helping patients fight the disease, they also produce side effects that can affect the hair, skin and nails and can significantly affect quality of life and, potentially, the ability to continue treatment, according to a press release issued here at the American Academy of Dermatology Summer Meeting. “Approximately half of patients who undergo immunotherapy and receive targeted cancer medications experience a skin-related reaction to the medication,” Anisha Patel, MD, FAAD, an associate professor of dermatology and internal medicine at the University of Texas MD Anderson Cancer Center in Houston, said in the…

Niraparib demonstrated clinically relevant activity among women with heavily pretreated ovarian cancer, particularly those with homologous recombination deficiency-positive, platinum-sensitive disease, according to findings from the phase 2 QUADRA study published in The Lancet Oncology. The results, which also showed no new safety signals, support extending the use of poly(ADP-ribose) polymerase (PARP) inhibitors to a wider population of women with late-line ovarian cancer, including those without BRCAmutations, according to the researchers. “This is another piece of the puzzle that helps our patients live longer,” Kathleen Moore, MD, associate director of clinical research at Stephenson Cancer Center at University of Oklahoma College of Medicine, said in a press…

TORONTO, CANADA / ACCESSWIRE / AUGUST 6, 2019 / Soricimed Biopharma Inc. (“Soricimed”), a clinical-stage pharmaceutical company developing first-in-class, targeted cancer therapeutics, announced today that The University of Texas MD Anderson Cancer Center (MDACC) has activated an Investigator Initiated Clinical trial of Soricimed’s lead drug candidate, SOR-C13 in late stage pancreatic cancer. This trial was initiated by Siqing Fu, MD PhD, a member of the Department of Investigational Cancer Therapeutics at MDACC, one of the world’s most respected cancer research centers, based on the results of Soricimed’s multi-center Phase 1 clinical trial in patients with late-stage solid tumor cancer. The Phase 1 trial…

– Milestone represents the first patient dosed with UltraCAR-T targeting solid tumors – First-in-class investigational therapy using autologous CAR-T cells targeting advanced, recurrent platinum resistant ovarian, fallopian tube or primary peritoneal cancer GERMANTOWN, Md., Aug. 5, 2019 /PRNewswire/ – Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the first patient has been dosed with Precigen’s PRGN-3005, a first-in-class investigational therapy using Precigen’s UltraCAR-Tâ„¢ therapeutic platform. PRGN-3005 UltraCAR-T is an autologous chimeric antigen receptor T (CAR-T) cell…

— Enhanced survival outcomes in DKK1-high gastroesophageal junction and gastric cancer patients – — DKK1-high biomarker enables future patient selection – — Live conference call and webcast with clinical investigators at 8:30 AM ET — CAMBRIDGE, Mass., Aug. 6, 2019 /PRNewswire/ – Leap Therapeutics, Inc. (NASDAQ: LPTX) today announced that its anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with Merck’s anti-PD-1 antibody, Keytruda® (pembrolizumab), demonstrated higher survival and objective response outcomes in patients with advanced gastroesophageal junction and gastric cancer (GEJ/GC) whose tumors expressed high levels of DKK1 (DKK1-high).  DKN-01 plus Keytruda therapy achieved over 22 weeks median progression-free survival (PFS) and nearly 32…

Early detection of HPV can prevent various forms of cancer in both men and women, including gay, transgender, and HIV-positive patients   PASADENA, Calif (August 6, 2019) – OmniPathology (www.omnipathology.com), a physician-owned medical laboratory specializing in state-of-the-art pathology services, today announced its new FISH (fluorescence in situ hybridization) test to detect human papillomavirus (HPV) related cancer in patients. What makes the test unique is that it is more accurate than other means used to detect HPV-related changes. The test has already been used to identify patients who otherwise would go untreated.   The new OmniPathology FISH test uses advanced fluorescence…

Twitter

Earn CME: https://naccme.com/program/7334 In this presentation from the ‘Keeping Up With CAR T-cell Therapies in B-Cell Lymphomas’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Matthew J. Frigault discusses best practices for the management of cytokine release syndrome (CRS) and neurotoxicity when utilizing CAR-T therapy. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/7333 In this presentation from the ‘Persistent Challenges in the Management of Follicular Lymphoma’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Elizabeth Brem provides and update on the treatment of relapsed/refractory follicular lymphoma. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7333 In this presentation from the ‘Persistent Challenges in the Management of Follicular Lymphoma’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. John P. Leonard provides an update on upfront and maintenance therapy advances in the treatment of follicular lymphoma. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7334 In this presentation from the ‘Keeping Up With CAR T-cell Therapies in B-Cell Lymphomas’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Caron A. Jacobson discusses the current state of CAR-T therapy in the treatment of lymphoma. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/7332 In this presentation from the ‘Confronting the Challenges of Peripheral T-Cell Lymphoma: Genomic Profiling and the Future Treatment Landscape symposium at the 2019 Great Debates and Updates in Hematologic Malignancies, Dr. Jasmine Zain discusses novel therapies and future targets for the treatment of peripheral t-cell lymphoma. © 2019 Imedex, an HMP Company

July 2, 2019 San Diego Supercomputer Center Researchers Find Novel Diagnosis Method    The invasive and expensive diagnosis process of bladder cancer, which is one of the most common and aggressive cancers in the United States, may be soon helped by a novel non-invasive diagnostic method thanks to advances in machine learning research at the San Diego Supercomputer Center (SDSC), Moores Cancer Center, and CureMatch Incorporated.   Research scientists Igor Tsigelny and Valentina Kouznetsova have been working on the development of a machine-learning (ML) model that looks at a patient’s metabolites and their chemical descriptors. The model accurately classifies the…

Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains how the landscape is changing in treating metastatic hormone-sensitive prostate cancer.

Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the anticipated trial results involving I-O, TKIs and biomarkers in renal cell carcinoma (RCC).

Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, discusses strategies for the 2nd line renal cell carcinoma (RCC) patients following I-O.

Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, provides perspective on treating newly diagnosed renal cell carcinoma (RCC) patients.

Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the studies and outcomes in sarcomatoid renal cell cancer and urothelial cancer.

Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the design on the outcomes of the PDIGREE trial in metastatic, untreated renal cell carcinoma.

Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atrium Health, UNC Chapel Hill School of Medicine shares the data in smoldering multiple myeloma (MM) presented at ASCO 2019.

Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atrium Health, UNC Chapel Hill School of Medicine provides outcomes from the MAIA study that compares daratumumab + lenalidomide + dexamethasone versus lenalidomide + dexamethasone in multiple myeloma elderly patients.

Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atrium Health, UNC Chapel Hill School of Medicine, compares intravenous daratumumab versus subcutaneous daratumumab.

Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center explains the results of the SOPHIA trial, a phase III study of chemotherapy plus margetuximab or trastuzumab in HER+ metastatic breast cancer.

Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center explains how CDK 4/6 inhibitors are being integrated into breast cancer treatment.

Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center provides the outcomes of the MONALEESA-& trial in premenopausal breast cancer.

Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of Medicine, Harvard Medical School provides an overview of the SOPHIA trial, a phase III of chemotherapy plus margetuximab or trastuzumab in HER+ metastatic breast cancer after pertuzumab with 1-3 prior lines of treatment.

Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of Medicine, Harvard Medical School elaborates on the efficacy and safety of combination eribulin and pembrolizumab in metastatic breast cancer.

Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of Medicine, Harvard Medical School shares the results of ImPassion130 study, a phase III adding atezolizumab to the 1st line chemotherapy with nab-paclitaxel in patients with PD-L1 positive metastatic triple-negative cancer (TNBC).

Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of Medicine, Harvard Medical School discusses the outcomes from the MONALEESA-7 trial in premenopausal metastatic breast cancer.         premenopausal metastatic breast cancer, monaleesa-7 trial, outcomes

Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center discusses the value of liquid biopsy and where it is ready for routine practice in CRC.

Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center addresses molecular profiling in the treatment of colorectal cancer (CRC).

Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center shares the results from the APACT study, a phase III trial involving adjuvant nab-paclitaxel plus gemcitabine versus gemcitabine alone for surgically resected pancreatic adenocarcinoma.

Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center addresses whether current data will change the way we treat colorectal cancer.

Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center evaluates the complexities of managing advanced/refractory metastatic colorectal cancer (mCRC).

Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope, opens up about the top challenges in managing non-small cell lung cancer (NSCLC) in patients.

Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope, explains how 2nd line patients who received Keytruda or other PD-L1 targeting agents can be treated.

Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope explains the ideal patient to receive Alimta plus Keytrude based on data and results from KEYNOTE-189.

Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope on treating non-squamous, non-small cell lung cancer (NSCLC) patients who express high levels of PD-L1.

Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope, identifies strategies for recognizing PD-L1 status.

Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope, showcases some molecular tests that are utilized prior to treating advanced NSCLC.

Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope addresses on germline mutations and the impact they have on non-small cell lung cancer (NSCLC) patients.

Naiyer Rizvi, MD Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical Center addresses on the future of non-small cell lung cancer (NSCLC) drug development.

Naiyer Rizvi, MD Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical Center provides his thoughts on the role of blood TMB versus tissue TMB as a biomarker for lung cancer patients.

Naiyer Rizvi, MD Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical Center explains the role of PD-L1 and TMB biomarkers in treating lung cancer with both single agent immuno-oncology (I-O) and I-O combinations.

Naiyer Rizvi, MD, Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical Center explains the results from KEYNOTE-001 which evaluated pembrolizumab in advanced non-small cell lung cancer (NSCLC).

Naiyer Rizvi, MD, Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical Center discusses biomarker roles in identifying lung cancer patients who are most likely to benefit from therapies.

Danny Rischin, MD, Division of Cancer Medicine, Department of Medical Oncology, Peter MacCallum Cancer Centre, Professor of Medicine, University of Melbourne discusses the updated data for the treatment of cutaneous squamous cell carcinoma (cSCC).

Danny Rischin, MD, Division of Cancer Medicine, Department of Medical Oncology, Peter MacCallum Cancer Centre, Professor of Medicine, University of Melbourne explains why stratification PD-L1 score in KEYNOTE-048 is important for head and neck cancer.

Danny Rischin, MD, Division of Cancer Medicine, Department of Medical Oncology, Peter MacCallum Cancer Centre, Professor of Medicine, University of Melbourne provides insight on KEYNOTE-048 investigating pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma.

Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the promise of bispecific antibodies in multiple myeloma (MM) treatment for patients.

Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the different combinations that are available and still in develop for the convenience of multiple myeloma (MM) patients.

Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains maintenance regimens for multiple myeloma (MM) patients.

Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers discusses the outcomes from the ECOD trial in smoldering multiple myeloma (MM).

Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers showcases the difference from daratumumab and isatuximab and whether the drug is showing promise as a treatment for MM.

Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the significance of the prolonged progression-free survival in patients with relapsed/refractory multiple myeloma (MM) if treating with isatuximab.

Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School describes the updated FORTE trial data in multiple myeloma (MM).

Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School provides results from the ECOG trial in smoldering multiple myeloma (MM).

Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School considers whether isatuximab can remain a treatment option for relapsed/refractory multiple myeloma (MM).

Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School discusses the prolonged progression-free survival in patients with relapsed/refractory multiple myeloma (MM) if treated with isatuximab.

Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology addresses the policies proposed to drig pricing.

Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology shares the transition from volume to value in the oncology space.

Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology describes the factors that influence cost in novel therapeutic interventions.

Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology explains the role of CDK 4/6 inhibitors in advanced breast cancer and discusses whether they are interchangeable in treatment planning for patients.

Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology shares the results of the ImPassion130, a phase III study that adds atezolizumab to 1st line chemotherapy with nab-paclitaxel in patients with PD-L1 positive metastatic triple negative breast cancer (TNBC).

Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology discusses the outcomes from the MONALEESA-7 trial in premenopausal, metastatic breast cancer.

William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai explains the results of KEYNOTe-365, pembrolizumab in metastatic castration-resistant prostate cancer (mCRPC).

William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai shares details on upcoming prostate cancer PARP inhibitor trials.

William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai elaborates on how biomarker selection trials may help identify in prostate cancer patients.

William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai explains the differences between the ENZAMET and TITAN studies.

William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai discusses the outcomes of the TITAN study in metastatic castration-sensitive prostate cancer (mCSPC).

Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber Cancer Institute discusses strategies for treating 2nd line renal cell carcinoma (RCC) patients following I-O in the 1st line.

Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber Cancer Institute considers a new approach to treating newly diagnosed renal cell carcinoma (RCC) patients.

Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber Cancer Institute explains the data on enfortumab in post-platinum and immuno-oncology (I-O) bladder cancer in patients is impressive enough to possibly change future practice habits.

Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber Cancer Institute offers his insight on the combination of ipilimumab + nivolumab in histologies of bladder cancer.

Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of Hope explains the design of the COSMIC-312 study in hepatocellular carcinoma (HCC) and speculates the potential this trial has.

Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of Hope, gives his take on the role of immuno-oncology (I-O) in managing hepatocellular carcinoma (HCC) considering the recent data.

Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of Hope, explains the outcomes from KEYNOTe 240 trial comparing pembrolizumab versus placebo in 1st line hepatocellular carcinoma (HCC) patients.

ASH 2016 Page 5 Update on CAR-T Cell Therapy in Lymphoma

ASH 2016 Page 4 Update on Antibody Therapies in Indolent Non-Hodgkin Lymphoma

ASH 2016 Page 3 Maintenance Therapy in Chronic Lymphocytic Leukemia

ASH 2016 Page 2 Update on New Chronic Lymphocytic Leukemia Drugs

ASH 2016 Page 1 Long Term Follow-up with Ibrutinib in CLL Patients

ASH 2016 Page 8 Leonard New Data for Mantel Cell and T-Cell Lymphoma Patients

ASH 2016 Page 7 Leonard Follicular Lymphoma Treatment Update

ASH 2016 Page 6 Leonard Update on Diffuse Large B Cell Lymphoma Treatments

New York, NY, June 28, 2019 – Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration(FDA) has approved ZIRABEVâ„¢ (bevacizumab-bvzr), a biosimilar to Avastin® (bevacizumab),[i] for the treatment of five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal cell carcinoma (RCC); and persistent, recurrent or metastatic cervical cancer.[ii]   “Biosimilars like ZIRABEV can help increase access to impactful therapies, driving market competition that may ultimately lower costs and help address the diverse needs of patients living with cancer,” said Andy Schmeltz, Global President, Pfizer…

Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health shares details on the CLL14 trial in chronic lymphocytic leukemia (CLL) that was presented at ASCO 2019.

Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health considers how CAR-T cell therapy may be combined to treat lymphomas

Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health discusses how impactful CAR-T cell therapy has been for the treatment of B-cell lymphomas.

Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health explains the results of the umbralisib phase II study involving patients with relapsed/refractory lymphoma.

Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope considers whether KRD will replace stem cell transplant as presented at ASCO 2019.

Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope discusses the future of isatuximab as an option in relapsed/refractory multiple myeloma.

Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope provides outcomes from the CASSIOPEIA trial that involves daratumumab + VTD in multiple myeloma.

Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope explains about the ECOG trial outcomes in smoldering multiple myeloma (SMM).

Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and Rosalie Kaplan Endowed Chair in Medical Oncology, City of Hope, describes the unmet medical needs in treating non-small cell lung cancer (NSCLC)

Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of Medicine at Harvard Medical School discusses an overview of some of the top challenges in managing non-small cell lung cancer (NSCLC).

Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of Medicine at Harvard Medical School explains how he would treat 2nd line patients who received Keytruda or another PD-L1 targeting agent as part of 1st line therapy.

Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of Medicine at Harvard Medical School decides on whether the results of the RELAY trial will impact the management of 1st line EGFR non-small cell lung cancer (NSCLC).

Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of Medicine at Harvard Medical School explains the standard approach to treating non-squamous non-small cell lung cancer patients with high levels of PD-L1.

Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of Medicine at Harvard Medical School elaborates the primary molecular tests that are utilized prior to treating advanced NSCLC.

Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of Medicine at Harvard Medical School discusses details on the study of U3-1402 in EGFR mutant non-small cell lung cancer (NSCLC).

Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of Medicine at Harvard Medical School outlines an overview of the advances in the treatment of lung cancer that was presented at ASCO 2019.

Dr. Kristin Higgins, MD, Associate Professor, Department of Radiation ONcology, Winship Cancer Institute of Emory University Medical Director, The Emory Clinic shares how radiation fits into treatment algorithms in stage 3 unresectable NSCLC considering the results of the PACIFIC study.

Dr. Kristin Higgins, MD, Associate Professor, Department of Radiation ONcology, Winship Cancer Institute of Emory University Medical Director, The Emory Clinic provides her interpretation of the data presented at ASCO 2019 from the PACIFIC Study investigating durvalumab in stage 3 unresectable non-small cell lung cancer (NSCLC).

Dr. Lowell Hart, MD, Director of Research, Florida Cancer Specialists and Research Institute explains the inhibitors currently being tested for breast cancer patients.

Dr. Lowell Hart, MD, Director of Research, Florida Cancer Specialists and Research Institute shares the mechanism of action for trilacicnib and the importance of protecting the bone marrow.

Dr. Lowell Hart, MD, Director of Research, Florida Cancer Specialists and Research Institute explains the outcomes from the phase II study of trilaciclib in small cell lung cancer (SCLC).

Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health elaborates on some of the top challenges he faces in managing non-small cell lung cancer (NSCLC).

Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health explains his take on how he would treat 1nd line patients who received Keytruda or other PD-L1 targeting agents as their 1st line therapy.

Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health shares the impact of the RELAY trial on his approach to managing first line EGFR mutant non-small cell lung cancer (NSCLC).

Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health discusses the implications of the Alimta plus Keytruda based on the updated results of KEYNOTE 189.

Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health shares the standard approach to treating patients who express high levels of PD-L1 in non-squamous, non-small cell lung cancer (NSCLC).

Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health explains the role of clinico-genomic data sharing in the development of new targeted therapies in lung cancer treatment.

Andre Goy, MD, Chairman and Director of the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and Chief of the Division of Lymphomas discusses how the approval of lenalidomide will impact how follicular lymphoma (FL) and marginal zone lymphoma (MZL) is managed.

Andre Goy, MD, Chairman and Director of the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and Chief of the Division of Lymphomas explains the promising role of CAR-T cell therapies in lymphoma patients.

Andre Goy, MD, Chairman and Director of the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and Chief of the Division of Lymphomas shares the exciting new data in lymphoma involving novel therapy for patients.

Talia Golan, MD, Head of Sheba Pancreatic Cancer Center shares the important role biomarkers have in the treatment of pancreatic cancer patients.

Talia Golan, MD, Head of Sheba Pancreatic Cancer Center describes the outcomes from the POLO study in pancreatic cancer and the importance of it.

Talia Golan, MD, Head of Sheba Pancreatic Cancer Center explains the potential of the POLO trial maintenance with olaparib in metastatic pancreatic cancer.

Richard S. Finn, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California explains the next phase of hepatocellular carcinoma (HCC) management and the research that is included.

Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of Hope offers the next steps if a hepatocellular carcinoma (HCC) patient fails 1st line therapy.

Richard S. Finn MD, Assistant Professor of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California offers his opinion on the role of immuno-oncology (I-O) in the management of hepatocellular carcinoma (HCC).

Richard S. Finn, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California explains the outcomes of hepatocellular carcinoma (HCC) in KEYNOTE-240 which compares pembrolizumab versus placebo in 1st line HCC.

What therapy should we use for DLBCL in 2016

CLL and Non-Hodgkin Lymphoma, What new drugs are on the horizon and why are they exciting

CLL, What is the significance of IGHV mutations and how are they assessed

What is the Role of Maintenance Therapy and What do you do After

CLL and non-hodgkin lymphoma, What are the risks and benefits of both ibrutinib and Idelalisib

Not Your Fathers CLL with Dr. John Pagel

CLL, Is there a role still for chemo AND who should get chemo

CLL, FCR vs BR Is One Better

Chronic Lymphocytic Leukemia Non-Hodgkin Lymphoma Should all HL patients be treated the same

Are vaccines dead in lymphoma and CLL

Are all DLBCL made equally

GRACEcast-133_Breast_Elderly Breast Cancer Part 4 Advanced and Functional Assessment of Patients

GRACEcast-132_Breast_Elderly Breast Cancer Part 3 Surgery and the Value of Adjuvant Therapy

GRACEcast-130_Breast_Elderly Breast Cancer Part 2 Prevention Screening and Goals of Treatment

GRACEcast-128_Breast_Older Women with Breast Cancer Part 1 Defining Population Trends by Age.mp4

What To Discuss With Your Healthcare Team – a Diagnosis of Triple Negative Breast Cancer – Litton

What makes a triple negative breast cancer negative Reis Filho

Review of Recent Progress in Immunotherapy in Triple Negative Breast Cancer Schmid

Current Standard of Care in Triple Negative Breast Cancer – Yardley

Combination therapy IO Chemo in Triple Negative Breast Cancer Schmid

BRCA Mutations What does it Mean When Choosing My Treatment Litton

Philadelphia, PA (June 4, 2019) – Oncoceutics, Inc. announced a publication in the Journal for ImmunoTherapy of Cancerdemonstrating ONC201 immunostimulatory activity in advanced cancer patients when given the recommended phase II dose (RP2D) of 625 mg orally every one week.  The publication, which describes a Phase I trial conducted by Mark Stein, MD, at the Rutgers Cancer Institute of New Jersey (CINJ) to evaluate weekly oral administration of the company’s lead compound ONC201, also confirmed previous studies, which demonstrated that the drug was well-tolerated. Weekly dosing stimulated intratumoral infiltration and activation of natural killer (NK) cells. The immune stimulatory effects that…

Bruce Feinberg, DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions considers the future of artificial intelligence being used by physicians.

Bruce Feinberg DO, VP Chief Medical Officer, Cardinal Health Specialty Solutions expresses some concerns surrounding artificial intelligence.

Bruce Feinberg, DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions comments on how artificial intelligence may evolve into a necessary decision-making tool for physicians.

Bruce Feinberg DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions discusses how artificial intelligence can increase efficiency and be more beneficial to physicians in the short term.

Bruce Feinberg DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions showcases real-world examples of artificial intelligence being used by physicians.

Bruce Feinberg, DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions explains the misunderstanding and complexity of artificial intelligence and how it can be used as a healthcare tool.

ASCO 2018 – Tarceva or Tarceva with Avastin as 1st Line for EGFR Pos. NSCLC vs. Tagrisso or Vizimpro

ASCO 2018: Combining Metformin with Standard EGFR Therapy

Imane El Dika, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center shares the next step for hepatocellular carcinoma (HCC) patient if the 1st line therapy fails.

Imane El Dika, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center explains the role of immuno-oncology (I-O) in the management of hepatocellular carcinoma (HCC) with the recent data provided.

Imane El Dika, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center discusses the outcomes of KEYNOTE-240 which compares pembrolizumab versus placebo in 1st line hepatocellular carcinoma (HCC).

Neelima Denduluri MD, Associate Professor, US Oncology Research, Virginia Cancer Specialists explains the results from the SOPHIA trial, a phase III study of chemotherapy plus margetuximab or trastuzumab in HER+ metastatic breast cancer.

Neelima Denduluri MD, Associate Professor, US Oncology Research, Virginia Cancer Specialists shares the results of the phase III EMBARCA trial that compares the efficacy and safety of talazoparib (TALA) to PCT (capecitabine, eribulin, gemcitabine, vinorelbine) in HER2-metastatic breast cancer patients.

Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center shares the results of ImPassion130, a phase III study adding atezolizumab to the 1st line chemotherapy with nab-paclitaxel in patients with PD-L1 positive metastatic triple-negative breast cancer (TNBC).

Neelima Denduluri MD, Associate Chair, US Oncology Research, Virginia Cancer Specialists explains the MONALESSA-7 trial outcomes in premenopausal metastatic breast cancer.

Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School comments on how myelodysplastic syndrome (MDS) patients who are ineligible for transplants can be managed.

Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School discusses the recent wave of approvals in AML and how it has changed treatment planning for patients.

Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School comments on the importance of the updated data on gilteritinib in acute myeloid leukemia (AML).

Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School elaborates on the phase III study of uproleselan with chemotherapy in patients with relapsed acute myeloid leukemia (AML).

Nancy A. Dawson MD, Professor of Medicine at Lombardi Cancer Center elaborates on the preferred agents on the 2nd line setting of renal cell carcinoma if a patient progresses on pembrolizumab/axitinib or ipilimumab/nivolumab.

Nancy A. Dawson MD, Professor of Medicine at Lombardi Cancer Center shares on how to decide between combinations of immuno-oncology (I-O) and TKIs for treating 1st line renal cell carcinoma (RCC).

Immunotherapies are amazing drugs against cancer. However, they still fail for too many patients. This video series presents IMPRES and TIDE, two of the best predictors of cancer immunotherapy outcomes. It also shows an easy way to combine them and improve their predictions. Finally, it makes suggestions of practical ways to contribute to research on this topic. You can support this work by making a donation: https://donorbox.org/better-predict-cancer-immunotherapy-results You can also ask for collaboration: https://mostaphabenhenda.typeform.com/to/fPEidr Text transcription: https://medium.com/the-ai-lab/how-to-better-predict-cancer-immunotherapy-results-f81747af75c8

Nancy A. Dawson MD, Professor of Medicine at Lombardi Cancer Center shares the TITAN Study outcomes, investigating apalutamide in metastatic castration-sensitive prostate cancer (mCSPC).

Nancy A Dawson MD, Professor of Medicine at Lombardi Cancer Center discusses her view on the ENZAMET Study while comparing testosterone suppression versus testosterone suppression + enzalutamide in metastatic hormone-sensitive prostate cancer presented at ASCO 2019.

Vincent Chung MD, Associate Clinical Professor and Medical Oncologist at City of Hope discusses details from APACT study, a phase III trial of adjuvant nab-paclitaxel plus gemcitabine.

Vincent Chung MD, Associate Clinical Professor and Medical Oncologist at City of Hope shares statistics and data on strategies that are emerging concerning BRCA mutations and pancreatic cancer.

Vincent Chung MD, Associate Clinical Professor and Medical Oncologist at City of Hope provides outcomes on the POLO Trial with olaparib in metastatic pancreatic cancer.

Kim Chi MD, Medical Oncologist, Senior Scientist at the BC Cancer Agency discusses upcoming prostate cancer PARP inhibitor trials and what the field will be evolving into soon.

Kim Chi MD, Medical Oncologist, Senior Scientist at the BC Cancer Agency elaborates on the importance of biomarker selection trials. Biomarker trials may help guide prostate cancer patients respond to therapies.

Kim Chi MD, Medical Oncologist, Senior Scientist at the BC Cancer Agency discusses the design differences between ENZAMET and TITAN studies presented at ASCO 2019.

Kim Chi MD, Medical Oncologist, Senior Scientist at the BC Cancer Agency explains what came out of the metastatic castration-sensitive prostate cancer (mCSPC) TITAN study.

Paul M. Barr MD, Associate Professor of Medicine at Wilmot Cancer Institute elaborates on the role of CAR-T cell therapy while in the treatment of B-cell lymphomas.

Paul M.Barr MD Associate Professor of Medicine at Wilmot Cancer Institute explains the results found of the RESONATE Trial that was evaluating ibrutinib versus ofatumumab in relapsed chronic lymphocytic leukemia (CLL).

Paul M. Barr MD Associate Professor of Medicine at Wilmot Cancer Institute discusses the data found in the recent CLL-14 study in chronic lymphocytic leukemia (CLL).

Paul M. Barr MD Associate Professor of Medicine at Wilmot Cancer Institute provides his opinion on ibrutinib in 1st line chronic lymphocytic leukemia (CLL).

Michael B. Atkins at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology follows up on the long-term Checkmate-004 in metastatic melanoma and provides outcomes from the study.

Michael B. Atkins at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology elaborates on the IMDC classification role in the treatment of decision-making.

Michael B. Atkins MD at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology provides some recent trial investigations using immuno-oncology and TKIs in renal cell carcinoma.

Michael B. Atkins MD at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology discusses the preferred agents in the 2nd line setting of RCC once a patient has progressed on pembrolizumab/axitinib or ipilimumab/nivolumab.

Michael B. Atkins MD at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology discusses how to select between different combinations of immuno-oncology and TKIs that are available and for the treatment of 1st line renal cell carcinoma (RCC).

Thomas A. Abrams Senior Physician and Assistant Professor of Medicine at Harvard Medical School explains the next steps a patient with hepatocellular carcinoma (HCC) can do if they fail the 1st line therapy with immunocology.

Thomas A. Abrams Senior Physician and Assistant Professor of Medicine at Harvard Medical School tells us his thoughts on KEYNOTE-62. This is investigating pembrolizumab in HER2, PD-L1 positive advanced gastroesophageal cancer.

Thomas A. Abrams, Senior Physician and Assistant Medical Professor at Harvard Medical School provides results about the APACT Study. APACT Study is a phase III trial of adjuvant nab-paclitaxel plus gemcitabine versus gemcitabine for surgically resected pancreatic adenocarcinoma.

Dr. Thomas A. Abrams, Senior Physician and Assistant Professor of Medicine at Harvard Medical School discusses whether the POLO Trial with olaparib in metastatic pancreatic cancer is practice changing with respect to patients.

Lung Cancer Video Library Mandarin – Consolidation Radiation After a Good Response to 1st Line.mp4

Lung Cancer Video Library Mandarin – Combinations of Immunotherapy Agents in Advanced NSCLC.mp4

Lung Cancer Video Library Mandarin -The Basics of Managing Immune Mediated Side Effects.mp4

Lung Cancer Video Library Mandarin – Tumor Mutation Burden Current Status.mp4